Cost of illness in rheumatoid arthritis in Germany in 1997-98 and 2002: cost drivers and cost savings.

@article{Kirchhoff2011CostOI,
  title={Cost of illness in rheumatoid arthritis in Germany in 1997-98 and 2002: cost drivers and cost savings.},
  author={Timm D. Kirchhoff and J{\"o}rg Ruof and Thomas Mittendorf and Markus Rihl and Michael Bernateck and Wilfried Mau and Henning Zeidler and Reinhold Ernst Schmidt and Sonja Merkesdal},
  journal={Rheumatology},
  year={2011},
  volume={50 4},
  pages={
          756-61
        }
}
  • Timm D. Kirchhoff, Jörg Ruof, +6 authors Sonja Merkesdal
  • Published in Rheumatology 2011
  • Medicine
  • OBJECTIVE Comparison of overall RA-related costs and of relative contribution of single-cost domains before and after the introduction of TNF-blocking agents in Germany. METHODS Two cohorts of RA outpatients (ACR '87 criteria) with long-standing disease are assessed in terms of disease-related costs and cost composition (n = 106 patients in 1997-98 and n = 180 patients in 2002 with similar patient characteristics). Full-cost analyses are performed including direct disease-related costs… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 20 CITATIONS

    Evaluating the consequences of rheumatoid arthritis

    VIEW 1 EXCERPT
    CITES BACKGROUND

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 20 REFERENCES

    The Hanover Consensus Group. German recommendations on health economic evaluation

    • JM Schulenburg, W Greiner, F Jost
    • Value Health
    • 2008

    [ Guidelines of the German Society of Rheumatology for employment of tumor necrosis factor - blocking substances . ] March

    • B Manger, H Michels, HG Nüsslein, M Schneider, J Sieper
    • Arthritis Rheum
    • 2008